Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, 18 to 75 years of age at Visit 1~* Asthma diagnosis for \>/= 12 months prior to the start of screening (Visit 1)~* Bronchodilator response during screening~* Pre-bronchodilator FEV1 40%-80% of predicted during screening~* On ICS (inhaled corticosteroids) 500-2000 mcg/day of fluticasone propionate DPI or equivalent for \>/= 6 months prior to the start of screening (Visit 1) with no anticipated changes throughout the study~* On an eligible second controller medication (LABA, LAMA, LTRA or theophylline within the prescribed dosing range)~* Uncontrolled asthma as defined by protocol both during screening period and at time of randomization~* Chest X-ray or computed tomography (CT) scan obtained within 12 months prior to screening or chest X-ray during screening period confirming the absence of other lung disease~* Demonstrated adherence with controller medication during the screening period~Exclusion Criteria:~* History of severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection~* Use of zileuton or roflumilast within 6 months prior to screening~* Maintenance oral corticosteroid therapy, defined as daily or alternate day oral corticosteroid maintenance therapy within the 3 months prior to Visit 1~* Treatment with systemic (oral, intravenous or intramuscular) corticosteroids within the 4 weeks prior to Visit 1~* Major episode of infection within 4 weeks prior to Visit 1 or treatment with oral antibiotics within 2 weeks prior to Visit 1~* Active parasitic infection within the 6 months prior to Visit 1~* Active tuberculosis requiring treatment within the 12 months prior to Visit 1~* Known immunodeficiency, including, but not limited to, HIV infection~* Evidence of acute or chronic hepatitis or known liver cirrhosis~* History of cystic fibrosis, chronic obstructive pulmonary disease, and/or other clinically significant lung disease other than asthma~* Known malignancy or current evaluation for a potential malignancy~* Current smoker or former smoker with a history \>10 pack years~* History of alcohol, drug or chemical abuse~* Initiation or change in allergen immunotherapy within 3 months prior to Visit 1~* Use of biologic therapy including omalizumab during 6 months prior to Visit 1~* Receipt of live/attenuated vaccine within 4 weeks prior to Visit 1~* Pregnant or lactating women~* Body mass index (BMI) \> 38 kg/m2~* Body weight \< 40 kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- lebrikizumab - highest dose (Type: EXPERIMENTAL): None
- lebrikizumab - lowest dose (Type: EXPERIMENTAL): None
- lebrikizumab - middle dose (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete